<DOC>
	<DOCNO>NCT02076646</DOCNO>
	<brief_summary>A prospective , open-label , multi-center , Phase I/II study L19IL2 combination Dacarbazine patient metastatic melanoma .</brief_summary>
	<brief_title>A Phase I/II Dose Escalation Study Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein Combination With Dacarbazine Patients With Metastatic Melanoma</brief_title>
	<detailed_description>A prospective , open-label , multi-center , Phase I/II dose escalation study cohort 3-6 patient metastatic melanoma assign receive escalating dose L19-IL2 combination fix dose Dacarbazine . After definition MTD RD phase II part study , 60 patient Stage IV M1a M1b melanoma randomize 1:1 ratio receive open label combination treatment RD ( Arm 1 ) DTIC monotherapy ( Arm 2 ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>1 . 1870 year age , inclusive 2 . Must histologically cytologically confirm cutaneous metastatic melanoma ( Stage IV ) . For Phase II part patient Stage IV M1a M1b enrol . 3 . Must measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) identify CT MRI scan within 28 day first study drug administration . 4 . Baseline LDH within normal range 5 . Maximal 1 line previous systemic treatment metastatic disease ( prior adjuvant melanoma therapy , e.g. , IFN , permit . 6 . For woman childbearing potential , negative pregnancy test within 72 hour prior first dose study treatment . 7 . Women reproductive potential must willing practice acceptable method birth control study 12 week last dose study medication . 8 . Men reproductive potential must willing practice acceptable method birth control study 12 week last dose study medication . 9 . Must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 10 . Life expectancy least three month 11 . Adequate organ function : serum creatinine ≤ 1.5 x ULN , total bilirubin ≤ 30 mM/L ( mg/dL , ≤ 2.0 mg/dL ) , hepatic transaminase ≤ 2.5 x ULN , alkaline phosphatase ≤ 2.5 x ULN . 12 . ANC count ≥ 1.5 x 10^9/L , platelet count ≥ 100 x 10^9/L , hemoglobin &gt; 9 g/dL 13 . Normal 12lead ECG normal bidimensional echocardiogram MUGA 14 . All toxic effect prior therapy must resolve grade ≤1 unless otherwise specify 15 . Willing able give write informed consent . 1 . Pregnant breastfeed female 2 . Primary ocular melanoma 3 . Primary mucosal melanoma 4 . Use investigational anticancer drug within 28 day 5 halflives , whichever longer , precede first dose DTIC L19IL2 5 . Prior radiation target lesion , unless clear progression lesion since radiotherapy 6 . A history know Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection 7 . History clinical evidence brain metastasis leptomeningeal disease 8 . Any malignancy patient diseasefree less 5 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix 9 . Treatment DTIC within 6 month start study 10 . Treatment Ipilimumab within 6 month start study 11 . Hypersensitivity DTIC 12 . Concomitant use drug know alter cardiac conduction 13 . Chronic use corticosteroid use management cancer noncancerrelated illness 14 . Unstable serious concurrent uncontrolled medical condition 15 . Inadequately controlled cardiac arrhythmia include atrial fibrillation 16 . History acute subacute coronary syndrome include myocardial infarction , unstable severe stable angina pectoris 17 . Heart insufficiency &gt; grade II NYHA criterion 18 . Uncontrolled hypertension 19 . Ischemic peripheral vascular disease 20 . Active infection incomplete wound heal . 21 . History evidence active autoimmune disease . 22 . Known history allergy intravenously administer proteins/peptides/antibodies 23 . History organ allograft.or allogeneic peripheral blood progenitor cell bone marrow transplantation 24 . Major trauma include surgery within 4 week prior enter study . 25 . Any underlying medical psychiatric condition opinion investigator make administration study drug hazardous hinder interpretation study result ( e.g . AE ) . 26 . Melanoma patient BRAF 600 E mutation amenable receive approve treatment able extend overall survival .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Interleukin</keyword>
	<keyword>IL2</keyword>
	<keyword>monoclonal</keyword>
	<keyword>antibody</keyword>
	<keyword>cytokine</keyword>
	<keyword>Dacarbazine</keyword>
	<keyword>metastatic</keyword>
	<keyword>melanoma</keyword>
	<keyword>tumor target</keyword>
	<keyword>Dose definition</keyword>
	<keyword>L19</keyword>
</DOC>